Ways2Capital Reviews : Glenmark Launches Helsinn's Akynzeo In India

Glenmark Pharma has exclusively launched Akynzeo, a fixed dose combination drug (netupitant 300mg/palonosetron 0.5mg). Akynzeo is a single-dose oral capsule for each chemotherapy cycle that covers both the acute and delayed phase of chemotherapy-induced nausea and vomiting.

The drug has been developed by Swiss company Helsinn and Glenmark has exclusive marketing rights of this drug in India and Nepal.

The oncology market in India is growing at the rate of 20% due to the increasing number of cancer cases. The market of cancer drug is estimated to be Rs4,600cr by 2018. While there are several options to treat cancer, market for chemotherapy is likely to be ~Rs2,000cr in 2018. Nausea and vomiting are two of the most feared cancer treatment-related side effects for cancer patients. We believe that, Akynzeo has significant revenue potential.

This product is already being marketed in the Europe, the US and several other countries. The patents on this drug are valid in the US until 2035.

Helsinn is a privately owned pharmaceutical group with an extensive portfolio of marketed cancer care products and a robust drug development pipeline.

Glenmark, recently, has entered into an exclusive licensing agreement with Seqirus Pty to commercialize Ryaltris in Australia and New Zealand. Company is also expecting NDA approval to Ryaltris which has been filed with USFDA in May 2018.
 
For Quick Trial – 8962000225 ✔ 
or mail us here: info@ways2capital.com 
or visit http://www.ways2capital.com 
✆ - 0731-6626191 | Toll Free - 1800-3010-2007
Give a Missed Call for Free Trial - 09699997717
Share on Google Plus Share on Pinterest

About Bhoomi Desai

0 comments: